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Abstract
Staphylococcus aureus bacteraemia (SAB) is a serious infection that demands prompt clinical attention for good outcome. To assess the
impact of intervention by infectious diseases physicians (IDPs) in cases with SAB, a retrospective cohort study of patients with SAB was
performed in a 1240-bed, university hospital in Japan, with the aim of comparing the management and outcome of patients during the
initial and the latter half of the intervention period,. Three hundred and forty-six patients with SAB during the 7-year period, from 2002
to 2008, were included, and 194 patients in the initial half of the period (from 2002 to 2005) were compared with 152 patients in the
later period (from 2006 to 2008). There was no signiﬁcant difference between the two groups with respect to patient’s clinical back-
ground, although more patients in the later period were receiving immunosuppressive treatment. The proportion of methicillin resistant
S. aureus was lower during the later period (56.2% vs. 43.3%; p 0.02). Echocardiography was used more frequently (37.1% vs. 64.5%;
p < 0.001). Infective endocarditis and metastatic infections were diagnosed more frequently (10.8% vs. 20.4%; p 0.01). Follow-up blood
cultures were obtained more regularly (52.1% vs. 73.7%; p <0.001) and therapy was more frequently administered for at least 14 days
(47.4% vs. 82.2%; p <0.001). The 30-day mortality improved during the intervention period (25.8% vs. 16.4%; p 0.04). The total number
of blood cultures received by the laboratory increased annually and the total number of consultations increased by approximately 1.6-
fold compared to 2002. Proactive intervention by IDPs raised awareness of optimal management of bacteraemia and improved the
adherence to the standards of care, which subsequently resulted in an improvement in the outcome.
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Introduction
Infectious diseases are major causes of morbidity and mortal-
ity and contribute to increased healthcare costs. Clinical
intervention by a multidisciplinary infection control team
including infectious disease physicians (IDPs) reduces hospi-
talization duration and treatment costs for infected patients
[1–3]. Although some studies suggest that intervention by
IDPs can improve the quality of management of infectious
disease [4–7], there is little evidence available to conﬁrm
that such intervention improves survival.
Antibiotics are prescribed by attending physicians (rather
than by specialist IDPs) in Japan, as they are in most Euro-
pean countries. In addition, few hospitals have infectious dis-
eases departments and IDPs are not routinely consulted
about patients with bloodstream infection (BSI). In 2002, we
started a hospital-wide, active clinical intervention by IDPs
for the treatment of all bacteraemic patients at our hospital
and found that mandatory intervention to treat candida BSI
improves prognosis [8]. In addition to mandatory interven-
tion for bacteraemia, IDP consultations are initiated by
request from an attending physician or by an IDP when labo-
ratory ﬁndings and the results of therapeutic drug monitor-
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ing are signiﬁcant, or when a speciﬁc antimicrobial agent is
prescribed.
Staphylococcus aureus bacteraemia causes considerable
morbidity and mortality in the hospital setting, and strategies
to improve the management and outcome of this condition
are needed [1,9,10]. Jenkins et al. [10,11] reported that man-
datory intervention by IDPs improves adherence, although
they did not demonstrate a statistically signiﬁcant improve-
ment in outcomes, possibly as a result of inadequate statisti-
cal power.
In the present study, we assessed the impact of 7 years of
systematic intervention and report distinct improvements
with respect to evaluation, treatment and outcome in
patients with S. aureus bacteraemia.
Materials and methods
Study setting and population
The study took place at Kyoto University Hospital, which is
a 1240-bed tertiary hospital that admits 340 000 patients/
year. Approximately 400–600 nosocomial BSIs are treated at
this hospital annually and S. aureus is the second most com-
mon cause (after coagulase-negative staphylococci) account-
ing for approximately 10% of BSI.
This retrospective cohort study compared the outcomes
of all patients with S. aureus bacteraemia between the initial
and the latter halves of an intervention period. Patients were
included if they had proven S. aureus bacteraemia, which was
deﬁned as at least one S. aureus-positive blood culture plus
a systemic inﬂammatory response. Patients with actual
re-infection (rather than relapse) could be included several
times. Data were excluded from analysis when patient sur-
vival or death could not be conﬁrmed by medical records.
The study periods comprised initial and later intervention
periods from 2002–2005, and from 2006–2008, respectively.
Data included age, sex, underlying conditions, location of
acquisition, primary focus, timing of antibiotic initiation, com-
plications and survival at 30 days after detection of S. aureus
in blood cultures.
Intervention
Mandatory intervention began in 2002. Six IDPs from the
Department of Infection Control and Prevention at Kyoto
University Hospital were immediately informed of a positive
blood culture. An IDP immediately assumed responsibility for
a patient with clusters of Gram-positive cocci in blood cul-
tures and provided recommendations directly to the attend-
ing physician regarding appropriate antibiotic therapy (i.e.
choice of drug including glycopeptides, dose regimen and
treatment period) and optimal management of the infection.
The content and validity of all interventions were discussed
at weekly meetings involving all IDPs with an independent
assessor. Catheter-related infection was deﬁned if the cathe-
ter tip grew >1 · 103 colonies of S. aureus in the absence of
an alternative source of infection. The modiﬁed Duke criteria
were applied to all suspected cases of infective endocarditis
[12,13].
Standards for the management of S. aureus bacteraemia
We developed key standards of care to evaluate and manage
S. aureus bacteraemia, which comprised: obtaining blood for
follow-up cultures within 5 days; administration of at least
14 days of antibiotic therapy for the bacteraemia; and investi-
gation for infective endocarditis by echocardiography. Further
evaluations, such as radiographic studies, were recommended
to the attending physicians if clinical resolution was delayed
regardless of appropriate antibiotic therapy. Practical 14- and
28-day regimens for uncomplicated and complicated patients,
respectively, were determined on the basis of current guide-
lines and recent literature [14–16]. However, because the
optimal treatment and appropriate classiﬁcation of S. aureus
bacteraemia remain undeﬁned, we established 14 days as the
minimal duration of therapy.
Assessment of general effects of the mandatory interven-
tion in cases of bacteraemia
We reviewed the numbers of blood cultures received by the
laboratory from any patients during the study period and the
trends of all consultations recorded by the Department of
Infection Control and Prevention in a database, as indicators
of general effects on laboratory use and liaison with IDPs.
Each consultation record was classiﬁed as ‘consultation with
attending physician’, ‘signiﬁcant laboratory results’, ‘antibiotic
prescription’ and ‘other’ when the intervention started.
Statistical analysis
For bivariate analyses, categorical variables were compared
by Fisher’s exact test and an unpaired t-test where appropri-
ate. The cumulative survival time between the day of the
ﬁrst blood culture results that were positive for S. aureus
and death or the last outpatient clinic visit during the study
period was calculated by the Kaplan–Meier method for all
patients. The difference in 30-day cumulative survival of
patients was tested by the Mantel–Cox test. The potential
factors associated with 30-day mortality of patients were
examined by the Cox proportional hazards regression analy-
sis. All covariates that differed signiﬁcantly between the initial
intervention period and the later intervention period in the
bivariate analysis were considered for model entry into the
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above mentioned multivariate analyses. Data were analyzed
with PASW for windows, version 18.0 (SPSS Inc., Chicago, IL,
USA). All p values were two-tailed and p <0.05 was consid-
ered statistically signiﬁcant.
Results
We reviewed the results from 346 patients with initially
S. aureus-positive blood cultures. The initial and the latter
intervention periods included 194 and 152 patients, respec-
tively. Table 1 shows that the patients’ demographic charac-
teristics and comorbidities were generally similar between
the two periods, although the proportion of methicillin-resis-
tant S. aureus (MRSA) was lower during the later interven-
tion period (56.2% vs. 43.3%; p 0.02), and the proportion of
patients who received immunosuppressants was higher dur-
ing the later period (19.6% vs. 28.9%; p 0.05).
Table 2 compares the two periods in terms of details of
the infection process, the clinical management and the 30-
day mortality. Echocardiography was applied more frequently
(37.1% vs. 64.5%; p <0.001), which led to the discovery of
more valvular vegetations (seven vs. ten patients) during the
later period. Infective endocarditis or early metastatic infec-
tion was identiﬁed more frequently (10.8% vs. 20.4%;
p 0.01). Follow-up blood samples for culture were obtained
more regularly (52.1% vs. 73.7%; p <0.001), and therapy was
more frequently administered for at least 14 days (47.4% vs.
82.2%; p <0.001). More patients with MRSA bacteraemia
received anti-MRSA drugs (vancomycin, teicoplanin or arbek-
acin) within 2 days of blood cultures being obtained (64.2%
vs. 89.4%; p <0.001).
The number of blood cultures increased annually to 1.7-
fold more that that obtained at the beginning of the study
period and the number of consultations also increased by
approximately 1.6-fold compared to 2002. The growth rate
in the number of consultations was higher for ‘consultation
with attending physicians’ than for ‘signiﬁcant laboratory
results’ (Fig. 1).
The 30-day mortality decreased from 25.8% during the ini-
tial intervention period to 16.4% during the later interven-
tion period (p 0.04 by the Mantel–Cox test) (Fig. 2). The
results of Cox multivariate regression analysis suggested that
appropriate timing of anti-MRSA drug, follow-up blood cul-
ture obtained, echocardiogram obtained and later interven-
tion period remained as a predictor for 30-day mortality
(Table 3).
Discussion
The present study has demonstrated that the setting up of a
system with mandatory involvement of IDPs can improve
the management and outcome in patients with S. aureus bac-
teraemia. Although, throughout the period of the investiga-
tion, IDPs were informed of cases by the laboratory and
were therefore able to intervene with advice, including
details of the approved regimen, they do not themselves
order investigations or prescribe antibiotics. Therefore, the
effectiveness of their mandatory involvement depends on
building a relationship of conﬁdence and trust. We consider
that this contributed to the improved results obtained in the
second period. The detailed evaluation of patients probably
increased the recognition of infective endocarditis and meta-
static infection [10]. This suggests that instances of endo-
carditis and metastatic infection remained undiagnosed and
were treated as uncomplicated infections before consistent
consultation was established. The rate of detected complica-
TABLE 1. Microbiological characteristics of causative isolates and clinical background of patients with Staphylococcus aureus
bacteraemia according to intervention period
2002–2005 (n = 194) Initial
intervention period
2006–2008 (n = 152) Later
intervention period p
Age 62.1 ± 18.2 63.2 ± 16.8 0.78
Female sex 73 37.6% 63 41.4% 0.50
Risk factor
Diabetes mellitus 42 21.6% 24 15.8% 0.21
Immunosuppressant 38 19.6% 44 28.9% 0.05
Haemodialysis 12 6.2% 9 5.9% >0.99
Malignancy 35 18.0% 29 23.6% 0.88
Post transplantation 28 14.4% 13 8.6% 0.97
Hospitalized in intensive care unit 18 9.3% 19 12.5% 0.38
Management provider at time of bacteraemia
Surgical 100 51.5% 72 47.4% 0.45
Medical 75 38.7% 62 40.8% 0.73
Paediatric 17 8.8% 24 15.8% 0.06
Obstetrics and gynaecology 2 1.0% 3 2.0% 0.65
Methicillin-resistant isolates 109 56.2% 66 43.4% 0.02
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tions during the initial intervention period was low. If the
actual incidence of complications did not differ during the
whole study period, it is likely that one reason for the
improved prognosis during the second phase is that more
complications were recognized, and thus more patients were
appropriately treated during this latter intervention period.
Another reason for the improved prognosis could be the
lower proportion of methicillin-resistant isolates. One study
has suggested that the mortality of MRSA bacteraemia is
higher than that of methicillin-susceptible S. aureus (MSSA)
bacteraemia [17]. However, the better overall prognosis
cannot be fully explained only by a reduction in the numbers
of resistant pathogens. In addition, 30-day mortality
improved, despite the higher proportion of patients receiving
immunosuppressants during the latter period.
The improved outcome in patients with MRSA bactera-
emia might be derived from the earlier administration of
optimal antibiotics during the second period. Several
prospective studies have shown that inadequate antibiotic
TABLE 2. Evaluation and classiﬁcation of Staphylococcus aureus bacteraemia and complications according to intervention
period
2002–2005 (n = 194) Initial
intervention period
2006–2008 (n = 152)
Later intervention period p
Primary source of infection
Intravascular catheter 64 33.0% 60 39.5% 0.26
Skin and/or soft tissue 42 21.6% 33 21.7% >0.99
Respiratory tract 9 4.6% 12 7.9% 0.26
Other 10 5.2% 6 3.9% 0.80
Unknown 69 35.6% 41 27.0% 0.10
Infective endocarditis 7 3.6% 10 6.6% 0.22
Metastatic infection 14 7.2% 21 13.8% 0.05
Endocarditis or metastatic infection 21 10.8% 31 20.4% 0.01
Vertebral osteomyelitis 7 3.6% 12 7.9% 0.09
Deep-tissue infection or abscess 2 1.0% 3 2.0% 0.66
Septic pulmonary emboli 3 1.5% 4 2.6% 0.70
Septic arthritis 2 1.0% 2 1.3% >0.99
Appropriate timing of anti-MRSA drug within 2 days 70/109 64.2% 59/66 89.4% <0.001
Follow-up blood culture obtained 101 52.1% 112 73.7% <0.001
Days of therapy ‡ 14 92 47.4% 125 82.2% <0.001
Echocardiogram obtained 72 37.1% 98 64.5% <0.001
30-Day mortality 50 25.8% 25 16.4% 0.04
MSSA 14/85 16.5% 11/86 12.8% 0.52
MRSA 36/109 33.0% 14/66 21.2% 0.12
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
FIG. 1. Trends of characteristics of consultations (bars) and number
of blood cultures obtained (solid line). The number of blood cultures
increased annually to 1.7-fold more than that obtained at the begin-
ning of the study period, and the number of consultations also
increased by approximately 1.6-fold compared to 2002. Growth rate
in number of consultations was higher for ‘consultation with attend-
ing physicians’ than for ‘signiﬁcant laboratory results’.
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FIG. 2. Kaplain–Meier survival curves (at 30 days) for patients in the
ﬁrst period and the second period (Mantel–Cox test: p 0.04).
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therapy is a signiﬁcant risk factor for mortality resulting from
S. aureus bacteraemia, with inadequate therapy being more
frequent in MRSA than in MSSA bacteraemia [18,19]. Lodise
et al. [20] reported that a delay in administering correct
therapy beyond a breakpoint as late as 45 h after obtaining
blood cultures is an independent predictor of infection-
related mortality. We essentially recommend the use of gly-
copeptides when Gram stains of positive blood cultures
reveal Gram-positive clusters of cocci because over 60% of
clinical staphylococcal isolates are methicillin-resistant at our
hospital. Aggressive treatment and optimal management
strategies are central to the management of S. aureus bacter-
aemia [21,22] and the earlier initiation of anti-MRSA drugs
may have substantially contributed to the improved progno-
sis in the present study. The value of intervention by IDPs
can be more readily assessed in patients with staphylococcal
bacteraemia as a result of the crtical therapeutic decision to
administer glycopeptides in this situation, whereas the impact
of IDP intervention on antibiotic use against Gram-negative
bacteraemia may be difﬁcult to demonstrate because broad-
range antibiotics are empirically administered to many septic
patients.
Our policy of active intervention resulted in a general
increase in the number of consultations with attending physi-
cians. The signiﬁcant increase in the number of blood cul-
tures and changes in consultation trends suggest that
attending physicians have become more cognisant of the con-
cept of optimal therapies for infectious diseases and the use-
fulness of IDP advice. The present study demonstrates that
the increased acceptance of such an intervention by attend-
ing physicians can improve subsequent outcomes of patients
with S. aureus bacteraemia.
Limitations that are generally inherent in historical cohort
studies apply to the present study. A potential confounding
effect exists because we compared ﬁndings from two con-
secutive periods, and there may have been other factors
inﬂuencing the differences observed. However, no major
changes such as the introduction of a new anti-MRSA drug
for treating S. aureus bacteraemia occurred during the study
period. We eliminated selection bias by including all patients
with S. aureus bacteraemia who presented at our hospital
during the study. Possible changes in practice that were not
evaluated in the present study, such as the management of
therapeutic drug monitoring for anti-MRSA drugs or the
administration of optimal antimicrobial therapy against con-
comitant infection as a result of our intervention, might have
affected patient prognosis in some way. The effects of such
changes, however, could be considered part of the beneﬁt
derived from active IDP involvement.
Proactive intervention by IDPs raised awareness of the
optimal management of bacteraemia and improved adherence
to the standard of care for patients with S. aureus bactera-
emia, which subsequently resulted in an improved outcome.
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